NASDAQ · ZNTL
Zentalis Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for ZNTL: Nov 9, 2026
Zentalis Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.58. The reported EPS for the same quarter last year was $-0.37.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.58 | $-0.42 | $-0.63 | 6 |
| Dec 2026 | $-0.58 | $-0.43 | $-0.66 | 6 |
| Mar 2027 | $-0.56 | $-0.43 | $-0.67 | 4 |
| Jun 2027 | $-0.55 | $-0.40 | $-0.69 | 4 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Zacks · Fintel · BNK Invest- RTTNews · Oct 19, 6:50 AM EDTZentalis Reports Interim OS Rates Of 15 Months In Cyclin-E1 PROC Patients Treated With Azenosertib(RTTNews) – Zentalis Pharmaceuticals Inc. (ZNTL), a clinical oncology company, on Sunday announced interim overall survival (OS) data from the Phase 2 DENALI Part 1b trial for azenosertib as a biomarker-driven treatment for ovarian cancer.
- RTTNews · Oct 19, 2:10 AM EDTZentalis Highlights Interim Survival Data From DENALI Part 1b Study Of Azenosertib In PROC(RTTNews) – Zentalis Pharmaceuticals, Inc. (ZNTL) announced that interim overall survival (OS) data from Part 1b of the Phase 2 DENALI (GOG-3066) trial evaluating azenosertib in platinum-resistant ovarian cancer (PROC) have been published in an abstract ahead of a rapid oral pres
- RTTNews · Aug 18, 11:02 AM EDTZentalis Pharma Closes $92.6 Mln Offering Of Shares; Stock Up(RTTNews) – Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical oncology company, announced that it has closed its previously announced underwritten public offering of 26.45 million shares and an additional 3.45 million shares sold pursuant to the underwriters' additional share pur
- RTTNews · Aug 14, 1:56 AM EDTZentalis Pharma Prices $80.5 Mln Offering Of Shares At $3.50 Per Share; Stock Down(RTTNews) – Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage oncology company, priced a public offering of 23 million shares at $3.50 per share. The total gross proceeds from the offering are expected to be $80.5 million, and the company plans to use the net proceeds to
- Zacks · Jul 20, 9:26 AM EDTZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?Zentalis shares climb 28% over the past three months as optimism builds around azenosertib's ovarian cancer program.
- RTTNews · May 22, 6:01 AM EDTZentalis To Present Part 1 Phase 1b MUIR Trial Results Of Azenosertib At ASCO 2026(RTTNews) – Zentalis Pharmaceuticals, Inc. (ZNTL), a clinical-stage biopharmaceutical company, announced on Thursday encouraging Part 1 results from the Phase 1b MUIR trial evaluating Azenosertib, which will be presented at the American Society of Clinical Oncology (ASCO) Annual
- RTTNews · Apr 13, 6:47 AM EDTStocks To Watch Today: IDYA, OGN, VRX, REPL…(RTTNews) – The following biotech stocks are seeing significant moves in premarket trading on Monday, ranging from surges of over 98% to drops of over 50%, following regulatory announcements or results from ongoing clinical trials.
- RTTNews · Apr 10, 10:00 AM EDTWeekly Buzz: MGNX Resumes LINNET; GSK Wins China Nod; FDA Okays Waters; NBIX Snaps Up SLNO(RTTNews) – This week's biotech landscape witnessed regulatory approvals across the U.S., Canada, and China, alongside the lifting of a clinical trial hold by the FDA, collaborations, acquisitions, discontinuations, and positive data readouts spanning multiple therapeutic areas.
- Fintel · Apr 9, 1:49 PM EDTZentalis Pharmaceuticals (ZNTL) Price Target Increased by 19.05% to 5.83The average one-year price target for Zentalis Pharmaceuticals (NasdaqGM:ZNTL) has been revised to $5.83 / share. This is an increase of 19.05% from the prior estimate of $4.90 dated March 25, 2026. The price target is an average of many targets provided by an
- RTTNews · Apr 9, 10:56 AM EDTZentalis Advances Azenosertib With 400mg Dose; Stock Up(RTTNews) – Zentalis Pharmaceuticals, Inc. (ZNTL) announced that 400mg once daily on a 5-days-on, 2-days-off schedule (400mg QD 5:2) has been selected as the pivotal monotherapy dose of Azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC).
- BNK Invest · Mar 27, 2:13 PM EDTFriday Sector Laggards: Manufacturing, Biotechnology StocksIn trading on Friday, manufacturing shares were relative laggards, down on the day by about 4.5%. Helping drag down the group were shares of AmpliTech Group, off about 33% and shares of LightPath Technologies down about 14.7% on the day. Also lagging the market Friday are biot
- RTTNews · Jan 11, 10:55 PM ESTAfter-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers(RTTNews) – Several biotech and healthcare names posted notable gains in after-hours trading on Friday, with investors showing renewed interest in companies tied to drug development, healthcare services, and financing updates.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Zentalis Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.